In the in vivo model, we selectively knocked down the CCL2 gene in astrocytes in the brains of mice using an adenovirus-containing GFAP promoter and CCL2 shRNA 21 days before NMO-IgG damage (Figures 5A, B). The gene discussed is GFAP; the disease is neuromyelitis optica.